Application of EGFR/HER2 receptor tyrosine kinase inhibitor in preparation of medicine for treating HER2 mutation cancer

A technology of inhibitors and uses, applied in the field of application of EGFR/HER2 receptor tyrosine kinase inhibitors in the preparation of drugs for the treatment of HER2 mutation cancer, capable of solving problems such as the effect of compounds of formula A not disclosed

Pending Publication Date: 2021-03-02
JIANGSU HENGRUI MEDICINE CO LTD
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, none of the above documents disclose the effect of the compound of formula A on the treatment of HER2-mutated cancers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of EGFR/HER2 receptor tyrosine kinase inhibitor in preparation of medicine for treating HER2 mutation cancer
  • Application of EGFR/HER2 receptor tyrosine kinase inhibitor in preparation of medicine for treating HER2 mutation cancer
  • Application of EGFR/HER2 receptor tyrosine kinase inhibitor in preparation of medicine for treating HER2 mutation cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Effects of compound A and lapatinib on the proliferation of ATCC H1781 cells cultured in vitro.

[0022] 1. Test drugs

[0023] Drug name: compound A dimaleate (batch number S0915100514), lapatinib di-p-toluenesulfonate (batch number 20090105). Preparation method: all prepared with DMSO.

[0024] 2. Cell lines

[0025] ATCC H1781 cells come from Shanghai Lung Hospital, the cells are HER2 mutation (InsG776V, C), the patient is a 66-year-old female Caucasian lung adenocarcinoma patient, cultured with PRIM 1640 medium containing 10% fetal bovine serum (FBS).

[0026] 3. Reagents and instruments

[0027] PRIM 1640 was purchased from Gibco BRL; fetal bovine serum was purchased from Gibco; multifunctional microplate reader was purchased from BioTek; sulforhodamine B (SRB) was purchased from Sigma.

[0028] 4. Test method

[0029] SRB protein staining was used to detect the inhibitory effect of drugs on the proliferation and growth of tumor cells. The main ste...

Embodiment 2

[0038] Example 2: Effect of compound A and lapatinib on the activity of HER2 recombinant protease in vitro

[0039] 1. Test drugs

[0040] Compound A (batch number SHR120201-002-06), and lapatinib (batch number SHR115758-010-17) were provided by Jiangsu Hengrui Medicine, and staurosporine was purchased from MedChem (Monmouth Junction, NJ) in the United States (batch number MC -2104).

[0041] 2. Recombinant protein

[0042] Recombinant human protein HER2 WT (Lot#W353-1) and five HER2 mutant proteins (A775_G776insYVMA: lot#Z1251-6; D769H: lot#K1683-5; D769Y: lot#P1688-9; V777_G778insCG: lot#Z1287-3 ; V777L: lot#K1850-3) were purchased from SignalChem (Richmond, BC V6V 2J2, CANADA). These recombinant proteins are polypeptides from amino acid 676 of HER2 protein to amino acid 1255 at the C-terminus, all of which were produced by baculovirus in Sf9 insects Expressed in cells, and the N-terminus is tagged with GST. The EGFR gene index number is NM_004448. The protein purity of...

Embodiment 3

[0049] Example 3: Effect of compound A and lapatinib on proliferation of HER2 mutant MCF10A cell line cultured in vitro.

[0050] 1. Test drugs

[0051] Drug name: compound A (lot number S0915151219), lapatinib (lot number SHR115758-010-17). Preparation method: all prepared with DMSO.

[0052] 2. Cell lines

[0053] MCF10A cells were purchased from ATCC, and the cells were used as mother cells. The vector GV341 was used to package overexpressed lentivirus, and then infected with lentivirus to establish 19 mixed clone stable cell lines, including empty vector control (NC), HER2 WT, HER2YVMAdup, P780_Y781insGSP , G776>VC, V777L, L755S, D769H, G776R, G776C, L755P, V842I, L866M, R896C, S310F, S310Y, G309A, G309E, and D769Y. All cells were cultured with DMEM / F12 medium plus 5% horse serum, 20ng / ml EGF, 10μg / ml insulin, 0.5μg / ml hydrocortisone, 1% penicillin / streptomycin (P / S) and 100ng / ml Cholera Toxin.

[0054] 3. Reagents and instruments

[0055] DMEM / F12 (Gibco, 10-092-CVR)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of an EGFR/HER2 receptor tyrosine kinase inhibitor in preparation of a medicine for treating HER2 mutation cancer, and particularly relates to application of acompound shown in the formula A or medicinal salt thereof to preparation of medicine for treating HER2 mutant cancer.

Description

[0001] This application is a Chinese patent application with the application number 201780000888.0, the application date is January 23, 2017, and the invention title is "Use of an EGFR / HER2 receptor tyrosine kinase inhibitor in the preparation of a drug for treating HER2 mutation cancer" divisional application. technical field [0002] Use of an EGFR / HER2 receptor tyrosine kinase inhibitor in the preparation of medicines for treating HER2 mutation cancer. Background technique [0003] Worldwide, lung cancer is the leading cause of cancer death in both men and women. According to the statistics of the "2015 China Cancer Registration Annual Report", the incidence and mortality of lung cancer occupy the first place in China. The morbidity and mortality of lung cancer both increase with age. Generally, the incidence of lung cancer rises significantly after the age of 40, reaches a peak at about 75 years old, and then decreases (Shi Yuankai, Sun Yan. Manual of Clinical Oncology....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4709A61K45/06A61K31/5377A61K31/517A61P35/00
CPCA61K31/4709A61K31/517A61K31/5377A61K45/06A61P35/00A61K2300/00C07D401/14
Inventor 邹建军周彩纯黄亚玲任胜祥张革曾晓玲杨昌永曹国庆
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap